Efficacy, safety and influencing factors of intra-calf muscular injection of bone marrow mononuclear cells in the treatment of type 2 diabetes mellitus-induced lower extremity vascular disease.
Efficacy, safety and influencing factors of intra-calf muscular injection of bone marrow mononuclear cells in the treatment of type 2 diabetes mellitus-induced lower extremity vascular disease. Exp Ther Med. 2017 Nov;14(5):5177-5185 Authors: Zhou HM, Liu F, Yang AG, Guo YQ, Zhou YR, Gu YQ, Yan BY, Li QH Abstract The efficacy, safety and impact of vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF) associated with the intra-calf muscular injection of bone marrow mononuclear cells (BMMCs) in the treatment of type 2 diabetes mellitus (T2DM)-induced lower extremity vascular disease (LEVD) were evaluated. Patients with T2DM-LEVD were randomly divided into a control group and BMMCs group to assess the efficacy and safety of the treatment; serum VEGF and bFGF levels were detected. The BMMCs group was divided into superior genicular artery (SGA) and inferior genicular artery (IGA) subgroups as well as low-dose and high-dose subgroups for the comparison of efficacy indices. The BMMCs group exhibited significantly improved indices (P0.05). The claudication distance in the IGA subgroup was significantly greater that in the SGA subgroup (P0.05). BMMC treatment for T2DM-LEVD was found to be safe and effective and had no significant impact on serum VEGF and bFGF levels in the short term; However, the degree of LEVD may affect its efficacy. PMID: 29201234 [PubMed]
Michele Podetta, Marc Pusztaszeri, Christian Toso, Michel Procopiou, Fr édéric Triponez, Samira Mercedes Sadowski
Ben van Ommen, Suzan Wopereis, Pepijn van Empelen, Hilde M. van Keulen, Wilma Otten, Marise Kasteleyn, Johanna J. W. Molema, Iris M. de Hoogh, Niels H. Chavannes, Mattijs E. Numans, Andrea W. M. Evers, Hanno Pijl
This article is protected by copyright. All rights reserved.
James S. Lawson, Brian Salmons, Wendy K. Glenn